The lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.
Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Advice for community physicians treating HER2+ breast cancer.
Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
P-BCMA-ALLO1 yielded lymphodepletion responses even among those with prior exposure to other CAR T-cell therapies or bispecific agents.
Investigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.
A recovery tracker and other digital tools may be useful in helping to manage patient symptoms following debulking surgery for gynecologic cancer, according to an expert from Memorial Sloan Kettering Cancer Center.
A Q&A session with the expert panel.
Experts discuss the process of assessing decision-making capacity in patients with cancer.
Experts discuss the process of assessing decision-making capacity in patients with cancer.
Panelists discuss how emerging data on chimeric antigen receptor T-cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for earlier treatment lines in relapsed/refractory multiple myeloma influence institutional decision-making factors for their implementation.
Learn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.
Panelists discuss the immune profiles of responders vs non-responders to pelabresib in myeloproliferative neoplasms (MPNs).
Panelists discuss how health care centers provide comprehensive long-term monitoring and support services for both patients receiving CAR T and their caregivers in the posttreatment period, including regular medical assessments and ongoing educational resources.
Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
Christine Chung, DO, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® about implications of blood-based molecular markers in pancreatic adenocarcinoma.
Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.